

HCV Common Abbreviations and Terms

US Food and Drug Administration (FDA)-Approved Antiviral Drugs for Hepatitis C Virus (HCV) Treatment

boceprevir (BOC)	an NS3/4A protease inhibitor (PI); approved in 2011
peginterferon alfa (PEG IFN)	a synthetic version of a substance normally produced in the body to fight infection; approved in 2001
ribavirin (RBV)	a nucleoside analogue, used in combination with at least 1 other drug; approved in 2001
telaprevir (TVR)	an NS3/4A PI; approved in 2011

Investigational Antiviral Drugs for HCV Treatment

This list is not necessarily comprehensive and is intended as an aid in following course presentations.

In Phase III Testing:

ABT-267	an NS5A inhibitor
ABT-333	an NS5B polymerase inhibitor
ABT-450/r	a ritonavir-boosted (/r) PI
asunaprevir	formerly BMS-650032; an NS3 PI
daclatasvir	formerly BMS-790052; an NS5A inhibitor
deleobuvir	formerly BI 207127; an NS5B polymerase inhibitor
faldaprevir	formerly BI 201335; an NS3/4A PI
ledipasvir	formerly GS-5885; an NS5A inhibitor
mericitabine	an NS5B polymerase inhibitor
narlaprevir	formerly SCH 900518; an NS3/NS4A inhibitor
simeprevir	formerly TMC435; an NS3/4A PI
sofosbuvir	formerly GS-7977; an NS5B polymerase inhibitor
vaniprevir	formerly MK-7009; an NS3/4A PI

In Phase II Testing:

BMS-791325	an NS5B polymerase inhibitor
danoprevir	formerly RG7227; an NS3/4A PI
VX-135	formerly ALS-2200; an NS5B polymerase inhibitor

Organizations, Conferences, and Legislation

AASLD	American Association for the Study of Liver Diseases
ASM	American Society for Microbiology
CROI	Conference on Retroviruses and Opportunistic Infections
DSMB	Data and Safety Monitoring Board
DHHS	Department of Health and Human Services
EASL	European Association for the Study of the Liver
IAS–USA	International Antiviral Society–USA
ICAAC	Interscience Conference on Antimicrobial Agents and Chemotherapy
NIH	National Institutes of Health

NIAID	National Institute of Allergy and Infectious Diseases
PPACA or ACA	Patient Protection and Affordable Care Act
WHO	World Health Organization

General Medical Terms

AE	adverse effect
AFP	alpha-fetoprotein
AKR	aldo-keto reductase
ALT	alanine aminotransferase
ART	antiretroviral therapy
ARV	antiretroviral
AST	aspartate aminotransferase
AUC	area under the curve
BLD	below the limit of detection
BLQ	below the limit of quantification
BMI	body mass index
cEVR	complete early virologic response
CC, CT, TT	IL28B gene polymorphisms
COPD	Chronic Obstructive Pulmonary Disease
CP or CTP Score	Child-Pugh Score or Child-Turcotte-Pugh Score
CSF	cerebrospinal fluid
DAA	direct-acting antiviral
DCP	des-gamma-carboxy-prothrombin
EGD	esophagogastroduodenoscopy
EIA	enzyme immunoassay
ELISA	enzyme-linked immunosorbent assay
EPO	erythropoietin
EOT	end of treatment
eRVR	extended rapid virologic response
ESLD	end-stage liver disease
ETR	end-of-treatment response
EVR	early virologic response
FIB-4	a test for hepatic fibrosis
Forns index	a test for hepatic fibrosis
GGT	gamma-glutamyl transferase
GT or gt	genotype
HA	hyaluronic acid
HAI	histological activity index; used to determine stage of liver disease
HbcAb	hepatitis B core antibody
HbcAg	hepatitis B core antigen
HbeAb	hepatitis B “e” antibody
HbeAg	hepatitis B “e” antigen
HBIG	hepatitis B immune globulin
HbsAb	hepatitis B surface antibody
HbsAg	hepatitis B surface antigen
HCC	hepatocellular carcinoma
HE	hepatic encephalopathy
HPS	hepatorenal syndrome
HVPG	hepatic venous pressure gradient
IFN	interferon alfa
IgG	immunoglobulin G

IL28B	a genotype that can help indicate likelihood of HCV treatment response to interferon
INR	International Normalized Ratio
IRES	internal ribosome entry segment
ISG	interferon-stimulated gene
LFT	liver function test
MELD	model for end-stage liver disease; a scoring system for assessing the severity of chronic liver disease
Metavir	a scoring system used to determine stage of liver disease
OLT	orthotopic liver transplantation
pEVR	partial early virologic response
P-gp	P-glycoprotein
PI	protease inhibitor
PR or P/R	peginterferon alfa and ribavirin
PT	prothrombin time
RAV	resistance-associated variant
RGT	response-guided therapy
RVR	rapid virologic response
SBP	spontaneous bacterial peritonitis
SVR	sustained virologic response
TIMP	tissue inhibitor of metalloproteinase
VL	viral load

Opportunistic Infections (OIs)

HAV	hepatitis A virus
HBV	hepatitis B virus
HCV	hepatitis C virus
HDV	hepatitis D virus
HEV	hepatitis E virus
HIV	human immunodeficiency virus